"Right now is by far the best opportunity I've ever
seen. It's like buying AOL in 1996 at $0.53 and selling
it at the top at $93."
This company may have a cure for blindness. The FDA
is singing its praises and having meetings on
approving it for its "Fast Track" Program.
The Advisory Committee did not issue a ruling yet, but
had many positive comments on the company.
Ironically, this good news coincided with a lockup
expiration, which caused a false selloff in the stock.
This creates the perfect buying opportunity.
If the FDA fast-tracks this treatment, you can bet your
bottom dollar that when it is announced this small,
unheard-of company could make an easy 375% gain -
or more - as the stock soars on the news.
Christian DeHaemer has prepared an urgent report for
247profits e-Dispatch readers.
I've appended it below. Don't let this rare opportunity
pass you by.
Best regards,
J. Christoph Amberger
Dear Friend,
Let me introduce myself. My name is Christian DeHaemer.
I've been working and investing on the cutting edge of
technology for more than eight years. In that time I've
made my readers are great deal of money trading on new
technology.
Right now is by far the best opportunity I've ever
seen. It's like buying AOL in 1996 at $0.53 and selling
it at the top at $93.
I'm not just whistling Dixie. My readers have gotten in
early on every new wave of high-tech investment. From
the rise of the Internet, to the mapping of human DNA,
to the emergence of nanotechnology - we've been there
making money.
In fact, from its inception in November 2000 to July
2004, my VIP trading service has generated total gains
of 3,684%!
That comes out to more than 1,053% every year!
And I get that number simply by adding up the winners
and subtracting the losers. The list is long and
profitable: 73% from Capstone, 206% from Navisite, 67%
from Intertrust, 64% from Lexar, another 206% from Kana
Software�
What's the next big technology that's going to make
early investors rich? There is a small and growing
group of people who believe that this is the last
generation that will be constrained by historical human
problems.
These people call themselves "transhumanists." They
think that the technology will soon arrive that will
enable humans to be stronger, smarter, healthier and
live up to twice as long as today. And after looking at
the evidence, I believe them.
Take a look�
Stories like these are commonplace:
"�stem cell therapy and biomolecular technology could
allow us to regenerate organs and transplant new ones
as needed, much like giving a car a tune-up or an oil
change."
--ABC Online
"Computer intelligence will surpass human intelligence
this year."
--BBC
"Drugs that used to seem like the stuff of science
fiction could transform athletes into superhuman
creatures�"
--San Jose Mercury News
And I'm not even talking about the astonishing science
that is now commonplace. Things like cloning, DNA
mapping, designer babies, nanotech molecular
manipulation, bionic limbs, or even laser eye
treatment.
No more aging!
You could be among the last generation that will die a
so-called "natural death" or, if you're lucky, you may
be in the first generation that lives to be 150.
One of the chief causes of aging is mutations in
mitochondrial DNA. Aubrey de Grey of Cambridge
University believes that scientists can use the
attributes of nuclear DNA - which doesn't mutate - to
transform mitochondrial DNA and slowdown the aging
process.
De Grey says that there is a "50-50 chance of
effectively reversing aging in 25 years."
You can make a fortune by investing in the same
companies that will save your life.
Red Zone VIP has a long history of detecting companies
like these. But it doesn't end there. That's why
subscribers are thrilled with the service. Here's what
some happy investors have to say about it�
"I sold AutoLiv today for a 65% profit. Thanks for the
recommendation both in and out."
--W.S.
"I purchased 3 calls on 12/30/03 at $1.00 and sold them
on 1/14/04 for $4.70. I'm not a big trader, but try to
buy as many recommendations as I can with my limited
funds. Thanks for helping me make some money on this
one."
--R.J.
"Great call on HRB - I got out yesterday with a 51%
gain in less than one and a half weeks. Keep up the
great work. Never had it so good so fast."
--R.M.
But I'm not here to brag about the past. I want to tell
you about the most exciting opportunity since the dawn
of mankind - literally.
We've found seven companies that are working to create
the "superhuman" of tomorrow. They are involved in
every aspect of the "transhuman" project� from creating
new organs, to finding a cure for Alzheimer's, to drugs
that manipulate hormone antibodies and increase
strength, to implantable microchips and silicone
nanotech solutions.
The first of these seven stocks is on the launch pad
and the countdown to blastoff has begun.
I don't have time to tell you about all seven of these
tremendous opportunities today. I have a pressing need
to tell you about a company that may have the cure for
macular degeneration. The anticipated fast-track
approval would almost certainly trigger a higher stock
price.
For those who don't know, macular degeneration is a
disease wherein the light-sensing cells of the eye
mysteriously malfunction and over time cease to work.
Victims lose all but their peripheral vision. This
generally affects people over 60 years old - the
fastest growing portion of our population.
Seeing profits, saving sight.
You may not have problems with your eyesight, but
chances are you know someone who does. In the US alone,
there are more than 1.6 million people suffering from
macular degeneration, with about 200,000 new cases
diagnosed every year. If approved, this would be the
company's first product on the market. It will be co-
marketed with Pfizer - a $244 billion company.
Right now, QLT and Novartis sell a product called
Visudyne that is the only approved treatment for "wet
macular degeneration," the smallest of the three types
of the disease.
The little-known company I'm talking about is trying to
get approval to treat all three types of the disease,
which could help it realize about US$1 billion a year
in sales. Obviously, if this happens, it will not only
improve the quality of life for millions of people but
also make a ton of money for those who invest early as
the stock goes through the roof.
Emergency meeting of the FDA.
Recent volume surges coupled with a buy signal from my
proprietary Tri-Directional Indicator suggest that the
FDA will grant fast-track approval.
You don't want to miss out. Put Red Zone VIP to work
for you. Visit this link for the Full Report:
http://www.youreletters.com/t/57829/3785361/646747/56/
Sincerely,
Christian DeHaemer
Founder, Red Zone VIP
P.S. Give Red Zone VIP a risk-free trial today, and
you'll get Three Premium Trading Services� Red Zone
Profits, EVS, and Red Zone VIP� all for one low price.
But this opportunity is limited: first come, first
served. No exceptions! So please hurry. Here's where to
learn all the details about the service:
http://www.youreletters.com/t/57829/3785361/646747/56/
===========================================
Keep the e-Dispatch coming to your mailbox!
If you enjoy reading the e-Dispatch, help us out by
"white-listing" our service... before delivery is interrupted.
You can find the details here:
http://www.youreletters.com/t/57829/3785361/134/56/
A big thanks in advance from your faithful e-Dispatch team.
===========================================
Now made available for e-Dispatch Readers Only!
Visit the 247profits e-Dispatch Blog. We update it daily.
It just another way for you to access our insights and
addictive stock market commentary.
To access the blog, visit:
http://www.youreletters.com/t/57829/3785361/367/56/
**NOTE TO AOL AND COMPUSERVE USERS: Please cut and paste the
links into your browser to access our special reports and other
offers.**
SPECIAL OFFER: As another 247profits e-Dispatch Membership
benefit, you have the opportunity to receive a FREE two-week
subscription to Investor's Business Daily.
10 FREE issues of Investor's Business Daily, the daily newspaper
for self-directed investors. Every issue of IBD includes stock
tables with IBD's exclusive SmartSelect Ratings, coverage of
institutional buying trends and 42 charts of top-rated stocks
currently advancing.
Here's where you can sign up:
http://www.youreletters.com/t/57829/3785361/391/56/
***********************************************
Copyright � 2004 by Taipan Group LLC. All rights reserved. The
Taipan Group's 247profits e-Dispatch is sent daily to a select
group of investors who share the courage and foresight to stay
ahead of today's markets. The Taipan Group unites the
stock-picking talents of several analysts and editors. We
publish a variety of monthly print newsletters, weekly and daily
trading alerts, and information services. Each of the services
is based on individual trading/investment philosophies or
vehicles and specific investment approaches.
Please note: It's not our intention to send email to anyone who
doesn't want it. If you would like to remove yourself from this
mailing list, please see the instructions at the
bottom of this message.
For more about us, and a summary of our editorial policy, please
read here
http://www.youreletters.com/t/57829/3785361/392/56/
and here
http://www.youreletters.com/t/57829/3785361/393/56/
Our Members Only service frequently referred to in the
e-Dispatch includes a subscription to TAIPAN, the monthly
communiqu� compiled by our Taipan Think Tank, as well as special
reports, rebates on conferences, and related information
services. For more information on how to enjoy full Membership
Privileges, please visit our home page:
http://www.youreletters.com/t/57829/3785361/394/56/
The Taipan Group's 247profits e-Dispatch is intended
specifically for mature investors with a strong sense of
individual responsibility who want to arbitrage different
viewpoints to optimize their personal investment strategy. We
reserve the right to remove readers we believe do not meet these
criteria from our distribution list without prior
notice.
You are welcome to distribute this message, at your discretion,
to others who you believe share the values of the Taipan Group.
NOTE TO OUR READERS: Taipan Group LLC or The Taipan Group's
247profits e-Dispatch does not act as an investment advisor or
advocate the purchase or sale of any security or investment.
Investments recommended in this publication should be made only
after consulting with your investment advisor and only after
reviewing the prospectus or financial statements of the company
in question.
Taipan Group LLC expressly forbids its writers from having a
financial interest in any security that they recommend to their
readers. Furthermore, all other employees and agents of Taipan
Group LLC and its affiliate companies must wait 24 hours before
following an initial recommendation published on the Internet,
or 72 hours after a printed publication is mailed.
*******
This email was sent to
[EMAIL PROTECTED]
because you or someone using your email address subscribed to
this service.
*******
To unsubscribe, click the following link or copy and paste it
into your browser:
http://www.youreletters.com/u?id=3785361N&u=http://www.247profits.com&l=dispatch
[Non-text portions of this message have been removed]
------------------------ Yahoo! Groups Sponsor --------------------~-->
$9.95 domain names from Yahoo!. Register anything.
http://us.click.yahoo.com/J8kdrA/y20IAA/yQLSAA/BCfwlB/TM
--------------------------------------------------------------------~->
<a href=http://English-12948197573.SpamPoison.com>Fight Spam! Click Here!</a>
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/kumpulan/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
